Table 1. Study characteristics.
| Study | Year | Country | Study design | CKD group |
|---|---|---|---|---|
| D’Ascenzo et al.20) | 2013 | Italy | Prospective, multicenter | eGFR ≥60 mL/min/1.73 m2, 30–59 mL/min/1.73 m2, 15-29 mL/min/1.73 m2 |
| Wessely et al.19) | 2012 | Germany | Retrospective, single center | Pre-procedural eGFR ≤60 mL/min, equivalent to CKD stage ≥3 |
| Dumonteil et al.21) | 2013 | France | Retrospective, multicenter | Normal eGFR (≥90 mL/min), mild (60–89 mL/min), moderate (30–59 mL/min), and severe (<30 mL/min) CKD and those on chronic hemodialysis |
| Yamamoto et al.24) | 2013 | France | Prospective, multicenter | eGFR ≥60 ml/min/1.73 m² (CKD stage 1 + 2), 30–59 ml/min/1.73 m² (CKD stage 3), 15–29 ml/min/1.73 m² (CKD stage 4) |
| Goebel et al.22) | 2013 | Germany | Prospective, single center | Normal kidney function, CKD stage 3 and worse |
| Nguyen et al.23) | 2013 | USA | Retrospective, single center | Mild or normal (GFR >60), moderate (30 <GFR ≤60), severe or dialysis (GFR ≤30 or preoperative dialysis) |
| Allende et al.25) | 2014 | Canada | Retrospective, multicenter | CKD stages 1–2 (eGFR ≥60 mL/min/1.73 m2), stage 3 (30–59 mL/min/1.73 m2), stage 4 (15–29 mL/min/1.73 m2) and stage 5 (<15 mL/min/1.73 m2) |
| Rahman et al.27) | 2015 | UK | Retrospective, single center | CKD group (eGFR <60 mL/min/1.73 m2) and no-CKD group (eGFR >60 mL/min/1.73 m2) |
| Ferro et al.26) | 2015 | UK | Prospective, multicenter | eGFR: ≥60 (CKD stages 1–2), 45–59 (CKD stage 3a), 30–44 (CKD stage 3b), 15–29 (CKD stage 4), <15 mL/min/1.73 m2 or on dialysis (CKD stage 5) |
| Thourani et al.29) | 2016 | USA | Retrospective, multicenter | None/mild RD (GFR >60 mL/min), moderate RD (GFR 30–60 mL/min), severe RD (GFR ≤30 mL/min) |
| Codner et al.28) | 2016 | Europe | Prospective, multicenter | eGFR >60 mL/min/1.73 m2 (group I), 31–60 mL/min/1.73 m2 (group II), ≤30 mL/min/1.73 m2 (group III), dialysis (group IV) |
| Lüders et al.32) | 2017 | Germany | Retrospective, multicenter | Structural abnormalities or genetic traits that point to kidney disease (CKD stage 1), normal or mild reduced renal function (CKD stage 2), moderate renal insufficiency (CKD stage 3), severe renal insufficiency (CKD stage 4), end-stage renal failure (CKD stage 5). |
| Gupta et al.30) | 2017 | USA | Retrospective, multicenter | Patients with CKD were identified using ICD-9-CM codes 35.05 and 35.06 |
| Hansen et al.31) | 2017 | USA | Retrospective, multicenter | CKD stage 1: eGFR >90 mL/min/m2, stage 2: GFR 60–89 mL/min/m2, stage 3: eGFR of 30–59 mL/min/m2, stage 4: GFR of 15–29 mL/min/m2, stage 5: eGFR <15 mL/min/m2 |
| Franzone et al.33) | 2018 | Switzerland. | Prospective, multicenter | None or mild renal dysfunction: eGFR ≥60 mL/min/1.73 m2, moderate renal dysfunction: eGFR 30–59 mL/min/1.73 m2, severe renal dysfunction eGFR ≤30 mL/min/1.73 m2 |
| Pineda et al.34) | 2019 | USA | Prospective, multicenter | None/mild (eGFR >60 mL/min/1.73 m²), moderate/severe (eGFR ≤60 mL/min/1.73 m²) |
| Yap et al.38) | 2020 | Singapore | Prospective, single center | CKD 1 (eGFR ≥90 mL/min/1.73 m2), CKD 2 (eGFR 69–89 mL/ min/1.73 m2), CKD 3 (eGFR ≥30–59 mL/min/1.73 m2), CKD 4 (eGFR ≥15–29 mL/min/1.73 m2), CKD 5 or ESRF (eGFR <15 mL/min/1.73 m2) |
| Li et al.37) | 2021 | USA | Retrospective, single center | eGFR >60, eGFR = 30–60, eGFR <30 |
| Bandyopadhyay et al.35) | 2020 | International | Prospective, multicenter | No CKD: eGFR ≥60 ml/min/1.73 m2, mild CKD: eGFR 45–59 ml/min/1.73 m2, moderate/severe CKD: eGFR <45 ml/min/1.73 m2 |
| Gracia et al.36) | 2020 | USA | Prospective, single center | CrCl ≥60 mL/min, CrCl 30–60 mL/min, CrCl <30 mL/min |
CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; GFR: glomerular filtration rate; ICD-9-CM: international classification of diseases, ninth revision, clinical modification; ESRF: end stage renal failure; CrCl: creatinine clearance